Drugs targeting mutated BRAF (e.g., vemurafenib/PLX4032) in melanoma have improved patients’ survival (Chapman et al., 2011; Flaherty et al., 2010; Joseph et al., 2010). This evidence concerns the gene BRAF and melanoma.